Loading
genetics
No description yet: the sentence for this tag has not been written. 9 records carry it: 9 people.
Related tags
9 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Brandon Wainwright Director and CEO of QIMR Berghofer Medical Research Institute · QIMR Berghofer Medical Research Institute Geneticist known for work on the genetic drivers of childhood brain cancer who became Director and CEO of QIMR Berghofer, a leading Australian medical research institute, in 2026. | Medulloblastoma | none | leadership, clinician-scientist, paediatric-oncology | ||
Eitan Friedman Oncogeneticist, Meirav High Risk Clinic, Sheba Medical Center; professor, Gray Faculty of Medical and Health Sciences, Tel Aviv University · Sheba Medical Center Mapped which inherited cancer variants recur in which Israeli communities, and showed that outside the Ashkenazi founder panel there is no shortcut: you have to sequence. | HR-positive / HER2-negative breast cancer, Ovarian cancer | none | clinician-scientist | ||
Eli Sprecher CEO, Tel Aviv Sourasky Medical Center (Ichilov) · Tel Aviv Sourasky Medical Center Dermatologist and geneticist who has been chief executive of Tel Aviv Sourasky Medical Center, a major Israeli academic hospital, since 2024. | none | none | leadership, clinician-scientist, dermatology | ||
Ephrat Levy-Lahad Director, Medical Genetics Institute, Shaare Zedek Medical Center; professor, Hebrew University-Hadassah Medical School · Shaare Zedek Medical Center Produced the evidence that made Israel the first country to offer BRCA testing to a whole population group, by measuring cancer risk in carriers found through healthy men rather than through cancer clinics. | HR-positive / HER2-negative breast cancer, Ovarian cancer | none | clinician-scientist, prevention | ||
John Burn Professor of Clinical Genetics, Newcastle University · Newcastle Cancer Centre / Northern Centre for Cancer Care The Newcastle geneticist whose CAPP2 trial showed that two years of aspirin cuts bowel cancer in people born with Lynch syndrome, a result that still shapes NHS advice. | Colorectal cancer, Early-onset colorectal cancer | none | colorectal, uk, prevention | ||
Mark E. Robson Chief of the Breast Medicine Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center New York breast oncologist and cancer geneticist who led OlympiAD, the trial that made olaparib the first PARP inhibitor approved for BRCA-mutated breast cancer. | Metastatic triple-negative breast cancer, Breast cancer | none | breast, trialist | ||
Rachel Michaelson-Cohen Gynaecologist and medical geneticist, Shaare Zedek Medical Center; chair of the Israeli Consortium harmonising national BRCA carrier care · Shaare Zedek Medical Center Led the work of turning nine Israeli high-risk clinics, which were each doing something different, into one national protocol for looking after the carriers the screening programme keeps finding. | HR-positive / HER2-negative breast cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma | none | clinician-scientist, policy | ||
Ronald Cohn President & CEO · The Hospital for Sick Children (SickKids) Clinical geneticist who leads The Hospital for Sick Children in Toronto, one of the world's largest paediatric academic health centres. | none | none | leadership, paediatrics | ||
Rosalind Eeles Professor of Oncogenetics, The Institute of Cancer Research; Consultant in Clinical Oncology and Cancer Genetics, The Royal Marsden NHS Foundation Trust · The Royal Marsden The oncogeneticist who found most of the common genetic variants that raise a man's risk of prostate cancer, and whose work is the reason the UK's first prostate screening programme is defined by a gene rather than by an age. | Prostate cancer, Localised prostate cancer, high and very high risk | none | prostate, uk, screening |
